Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

NZ Pharmac saves, but says no to imatinib mesylate

    • 6 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    NZ Pharmac saves, but says no to imatinib mesylate. Pharmacoecon. Outcomes News 374, 12 (2002). https://doi.org/10.1007/BF03279440

    Download citation

    Keywords

    • Imatinib
    • Chronic Myeloid Leukaemia
    • Outcome News
    • Mesylate
    • Cetirizine